UnfoldIPThemesResearch

Company patents

CLEXIO BIOSCIENCES LTD.

CLEXIO BIOSCIENCES LTD. surprisingly shows a significant decline across most of its patent categories, with its core "Pharmaceutical Preparations" category decreasing by 33.3% in 2025 and 60.0% so far in 2026. While "Therapeutic Activity (Pharma)" saw a 100.0% YoY growth in 2024, it has since declined, indicating a potential shift away from new filings in these areas, especially in medical device-related categories like "Drug Delivery Devices" and "Pharmacy Containers / Devices" which saw 100.0% declines in 2025.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

46 US filings (since 2023) · 7 categories · 1 themes

Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical PreparationsDrug Delivery Devices
Who else files here? →
16since 2023
-33.3%YoY

Patents

Showing 1-10 of 101

Page 1 of 11
US 12589083 B2GRANTED
A61K31/135

Abuse-deterrent dosage forms containing esketamine

Filed:2021-11-10Pub:2026-03-31
Applicant:Clexio Biosciences Ltd.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

US 20260053757 A1APPLICATION
A61K31/135

DOSAGE REGIME WITH ESKETAMINE FOR TREATING NEUROPSYCHIATRIC OR NEUROLOGICAL CONDITIONS

Filed:2025-10-30Pub:2026-02-26
Applicant:CLEXIO BIOSCIENCES LTD.

The present disclosure provides methods for safe and efficacious administration of esketamine.

US 20260021058 A1APPLICATION
A61K31/135

ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER

Filed:2025-09-30Pub:2026-01-22
Applicant:CLEXIO BIOSCIENCES LTD.

The present invention provides a dosage regimen for safe and efficacious administration of esketamine and rapid-acting antidepressants in the treatment of major depressive disorder (MDD)

US 12514831 B2GRANTED
A61K31/135

Method of treating major depressive disorder

Filed:2023-11-14Pub:2026-01-06
Applicant:Clexio Biosciences Ltd.

The present invention provides a method for safe and efficacious administration of esketamine.

US 12478592 B2GRANTED
A61K31/135

Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Filed:2020-12-29Pub:2025-11-25
Applicant:CLEXIO BIOSCIENCES LTD.

The present invention provides a method for safe and efficacious administration of esketamine.

US 20250312293 A1APPLICATION
A61K31/135

ESKETAMINE FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER

Filed:2025-06-20Pub:2025-10-09
Applicant:CLEXIO BIOSCIENCES LTD.

The present invention provides a dosage regimen for safe and efficacious administration of esketamine and rapid-acting antidepressants in the treatment of major depressive disorder (MDD)

US 20250281428 A1APPLICATION
A61K31/135

Method Of Treating Major Depressive Disorder

Filed:2025-05-21Pub:2025-09-11
Applicant:Clexio Biosciences Ltd.

The present invention provides a method for safe and efficacious administration of esketamine.

US 12364672 B2GRANTED
A61K31/135

Esketamine for use in treating major depressive disorder

Filed:2019-10-11Pub:2025-07-22
Applicant:CLEXIO BIOSCIENCES LTD.

The present invention provides a dosage regimen for safe and efficacious administration of esketamine and rapid-acting antidepressants in the treatment of major depressive disorder (MDD).

US 12336970 B2GRANTED
A61K31/135

Method of treating major depressive disorder

Filed:2023-11-22Pub:2025-06-24
Applicant:Clexio Biosciences Ltd.

The present invention provides a method for safe and efficacious administration of esketamine.

US 20250195454 A1APPLICATION
A61K31/135

METHOD OF TREATING MAJOR DEPRESSIVE DISORDER

Filed:2025-03-06Pub:2025-06-19
Applicant:Clexio Biosciences Ltd.

The present invention provides a method for safe and efficacious administration of esketamine.

12345…11